Bank of America’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,932,406
| Closed | -$76.8M | – | 5691 |
|
|
2026
Q1 | $76.8M | Buy |
1,932,406
+982,862
| +104% | +$25.1M | 0.01% | 1309 |
|
|
2025
Q4 | $23.7M | Buy |
949,544
+396,537
| +72% | +$10M | ﹤0.01% | 2146 |
|
|
2025
Q3 | $13.4M | Buy |
553,007
+417,209
| +307% | +$7.42M | ﹤0.01% | 3002 |
|
|
2025
Q2 | $1.78M | Sell |
135,798
-71,230
| -34% | -$902K | ﹤0.01% | 4878 |
|
|
2025
Q1 | $2.98M | Buy |
207,028
+163,320
| +374% | +$2.67M | ﹤0.01% | 4317 |
|
|
2024
Q4 | $732K | Sell |
43,708
-269,630
| -86% | -$4.47M | ﹤0.01% | 5274 |
|
|
2024
Q3 | $5.01M | Buy |
313,338
+240,061
| +328% | +$2.94M | ﹤0.01% | 3730 |
|
|
2024
Q2 | $662K | Sell |
73,277
-3,707
| -5% | -$35.2K | ﹤0.01% | 5163 |
|
|
2024
Q1 | $870K | Buy |
76,984
+39,954
| +108% | +$378K | ﹤0.01% | 5011 |
|
|
2023
Q4 | $295K | Sell |
37,030
-14,913
| -29% | -$100K | ﹤0.01% | 5843 |
|
|
2023
Q3 | $336K | Buy |
51,943
+47,732
| +1,134% | +$327K | ﹤0.01% | 5585 |
|
|
2023
Q2 | $26.1K | Buy |
4,211
+2,926
| +228% | +$13.9K | ﹤0.01% | 6645 |
|
|
2023
Q1 | $4.95K | Sell |
1,285
-707
| -35% | -$2.59K | ﹤0.01% | 7073 |
|
|
2022
Q4 | $6.17K | Buy |
1,992
+1,826
| +1,100% | +$6.77K | ﹤0.01% | 7025 |
|
|
2022
Q3 | $0 | Sell |
166
-5,880
| -97% | -$26.9K | ﹤0.01% | 7875 |
|
|
2022
Q2 | $29K | Sell |
6,046
-38,131
| -86% | -$244K | ﹤0.01% | 7051 |
|
|
2022
Q1 | $396K | Sell |
44,177
-35,068
| -44% | -$320K | ﹤0.01% | 5994 |
|
|
2021
Q4 | $892K | Buy |
79,245
+76,446
| +2,731% | +$1.03M | ﹤0.01% | 5399 |
|
|
2021
Q3 | $46K | Buy |
2,799
+401
| +17% | +$8.3K | ﹤0.01% | 7082 |
|
|
2021
Q2 | $54K | Buy |
+2,398
| New | +$56.4K | ﹤0.01% | 6798 |
|
Bank of America's CNTA Position: Q2 2026 in Review
Bank of America sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,932,406 shares — an estimated $76.8M sold.
Bank of America first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $76.8M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Bank of America reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of America sold 1,932,406 Centessa Pharmaceuticals shares in Q2 2026, an estimated $76.8M.
- Bank of America first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- Bank of America's Centessa Pharmaceuticals position peaked at $76.8M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.